MNOV · Medicinova Inc · Metrics
Market Cap
$68.91M
Shares
49.22M
Volume · Oct 20
16.31K
Avg daily vol (3M)
322.48K
MNOV metrics
71 of 122 screener metrics currently available.
Market overview
2 metricsShare price
$1.40
Market cap
$68.91M
Price action
20 metricsPrice change (1W)
-9.1%
Price change (30D)
-57.6%
Price change (3M)
+4.5%
Price change (6M)
-4.8%
Price change (YTD)
+6.9%
Price change (1Y)
+13.8%
Trailing year
Price change (5Y)
-62.9%
52-week high
$3.45
52-week low
$1.18
Change from 52-week high
-59.4%
Change from 52-week low
+18.6%
Annualized volatility
86.0%
Annualized volatility (3M)
118.3%
Beta
0.7
RSI (14D)
35.3
Price vs SMA 50
-21.2%
Price vs SMA 200
-7.6%
Avg volume (3M)
322,481
Relative volume
0.5
Average dollar volume
$891,026
Company
3 metricsSector
Healthcare
Industry
Biotechnology
Shares outstanding
49.22M
Valuation
12 metricsP / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
75.9×
reciprocal yield 1.3%
P / book
1.9
reciprocal yield 53.3%
FCF yield
-13.1%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-15.4%
Historical valuation
8 metricsP / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—
Dividends & buybacks
7 metricsDividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—
Earnings calendar
2 metricsNext earnings
—
Last earnings
—
Profitability
9 metricsGross margin
—
Operating margin
-3,242.5%
Trailing 12 months
Net margin
-2,928.8%
Gross profit (TTM)
—
Operating profit (TTM)
−$11.85M
Net income (TTM)
−$10.75M
Trailing 12 months
Diluted EPS (TTM)
$-0.21
FCF margin
—
Effective tax rate
—
Growth
11 metricsRevenue growth YoY
+240.6%
Year over year
Net income growth YoY
—
Revenue (TTM)
$920,481
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+0.4%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—
Quality
14 metricsReturn on equity
-28.9%
Return on assets
-26.6%
Debt / equity
—
Current ratio
8.8
EBITDA (TTM)
−$11.83M
Free cash flow (TTM)
−$9.12M
Quick ratio
8.8
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$25.42M
Total assets
$40.43M
Total debt
—
Cash flow & spend
7 metricsOperating cash flow (TTM)
−$9.11M
Capital expenditures (TTM)
$13,724
R&D (TTM)
$5.10M
SG&A (TTM)
—
Stock compensation (TTM)
$922,783
R&D / revenue
—
Stock compensation / revenue
—
Ownership (13F)
9 metrics13F filers
29
13F filer change QoQ
-1
Institutional ownership
10.5%
Conviction holders (share of 13F filers)
3.4%
Crowding (high-turnover and private-fund holders)
3.1%
Private-fund adviser ownership
3.0%
Active holders' share change QoQ
-8.9%
Holder tenure
17.7
Price vs estimated holder cost
-32.9%
Ownership (registered funds)
1 metricsIndex-fund ownership
2.6%
Short interest
3 metricsShort interest
0.7%
Latest settlement · 1.0 days to cover
Days to cover
1.0d
Short-squeeze score
27 / 100
Insider activity
2 metricsNet insider buying (90D)
—
Insider-sentiment score
—
Risk flags
1 metricsGoing concern
—